AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Xenon Pharmaceuticals reports 90.9% seizure reduction in X-TOLE OLE study.
ByAinvest
Friday, Dec 5, 2025 9:07 am ET1min read
Xenon Pharmaceuticals reports significant reductions in seizure frequency in a long-term trial of azetukalner, with 38% of participants achieving at least one year of seizure freedom. Four real-world study posters highlight the burden of depression and antiepileptic medication titration on people with epilepsy. Preclinical data suggests potential to improve motor function in Dravet syndrome through potentiation of NaV1.1.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet